UK Approves Second Weight-Loss Pill as EU Access Falls Behind

A decision on whether Britain’s National Health Service will cover the drug is expected in November.

Two oral GLP-1 medicines are now licensed in Britain. Across the Channel, patients are still waiting on one of them, and even the pill the EU has approved is stuck behind a wall of national funding decisions that has nothing to do with whether the drug works.

On 10 August 2026, the Medicines and Healthcare Products Regulatory Agency authorised orforglipron for weight management and type 2 diabetes, the Eli Lilly tablet sold as Foundayo. The regulator was explicit about the significance: this makes the UK the first country in Europe to license the medicine.

It is the second time in two months that Britain has got there first. The pattern is starting to look deliberate rather than accidental, and it says something interesting about where Europe’s obesity medicines market is heading. As access to new treatments expands, more patients are also looking for trusted ways to buy Mounjaro online UK, reflecting the growing demand for convenient and medically supervised weight-loss treatment.

What Britain has licensed

Orforglipron is authorised for adults with a BMI of 30 or above, or a BMI between 27 and 30, alongside at least one weight-related condition, used with a reduced-calorie diet and more physical activity. A second indication covers glycaemic control in type 2 diabetes that is not adequately managed.

The tablet is taken once daily at any time, with no food or water restrictions, starting at 0.8 mg and stepping up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg with at least a month at each level.

That absence of timing rules is the commercially significant bit. It is the one thing orforglipron does that its direct rival cannot.

Where the EU actually stands

The comparison is not simply Britain fast, Europe slow. It is more specific than that.

For oral semaglutide, the EU is close behind. The EMA’s Committee for Medicinal Products for Human Use issued a positive opinion in May 2026, and the European Commission granted marketing authorisation for the Wegovy pill on 15 July 2026. Novo Nordisk noted it was the company’s fifth approval for the tablet, after the United States, the UK, the UAE and Bahrain. Britain beat the EU by roughly five weeks.

For orforglipron, the gap is wider and currently open-ended. Lilly won FDA approval in April 2026 and has said it filed in more than 40 countries, but no EU authorisation has been granted and no decision date has been published. UK prescribers can write for it now. Their counterparts in Dublin, Madrid and Berlin cannot.

It’s worth noting that the two weight-loss figures come from different trials with different designs and populations, so they are not a fair head-to-head. Oral semaglutide performed strongly in the OASIS 4 study, where roughly one participant in three lost at least a fifth of their body weight. Orforglipron trades some efficacy for convenience.

Why Britain keeps arriving first

Brexit gave the MHRA a problem and, eventually, a tool.

Losing access to the EU centralised procedure meant the UK risked becoming an afterthought, a small market that companies filed in late. The response was the International Recognition Procedure, live since January 2024, which lets the MHRA lean on assessments already completed by seven trusted regulators, including the FDA, Swissmedic, Health Canada and the EMA itself. Route A runs to 60 days, and Route B to 110.

The mechanics matter here. If a company files in the EU first, UK approval tends to follow the European decision by a few weeks. If it files with the FDA first and then uses that approval as the reference, Britain can leapfrog the EU entirely. With orforglipron cleared in Washington in April, that second path was available.

Britain has also started stitching licensing and funding together. A joint MHRA and NICE pathway launched on 1 April 2026 runs the marketing authorisation review and the health technology assessment in parallel rather than one after the other, with the aim of shaving three to six months off the wait for some medicines.

None of this makes the MHRA a soft touch. Julian Beach, its executive director of healthcare quality and access, described the orforglipron decision as following a rigorous assessment of safety, quality and effectiveness and confirmed the agency will keep the tablet under close review. Reliance is not rubber-stamping. But it does remove duplicated work.

The catch nobody should skip past

Here is where the triumphant version of this story falls apart.

A licence tells you a medicine can be sold. It tells you nothing about whether anyone will pay for it. Orforglipron is not available on the NHS and will not be until NICE completes its appraisal, which is scheduled to publish on 18 November 2026. Until then the route is a private prescription, paid for by the patient.

That is exactly what happened with the Wegovy pill. Approved in June, on sale in private UK pharmacies from July, with NHS availability a separate and slower conversation.

Henry Gregg, chief executive of the National Pharmacy Association, welcomed the orforglipron decision while warning that the NHS rollout of weight management treatment remains too slow and that eligible patients face a postcode lottery depending on where they live. His argument is that community pharmacy could carry a much larger share of this work than it currently does.

So Britain is first to license and still rationing access. Speed at the regulator has not translated into speed at the pharmacy counter for anyone relying on public funding.

Europe’s problem is bigger than the EMA

If the UK’s bottleneck is NICE, the EU’s is roughly twenty-seven bottlenecks.

Central authorisation from the European Commission applies across every member state, which sounds like an advantage until you remember that pricing and reimbursement stay national. A medicine can be legal in Portugal and unaffordable there, legal in Germany and refused by the insurer.

Germany is the sharpest example, and it is the largest pharmaceutical market on the continent. Weight-loss medicines are excluded from statutory health insurance as lifestyle drugs, a position the Federal Joint Committee has traced back to a legal resolution from 2004. That stance has held up under challenge: a regional social court ruled again in 2026 that weight-loss injections sit outside the statutory benefits catalogue, and the federal health ministry has signalled no near-term change. Around nine in ten Germans are covered by those statutory plans. Most who want treatment pay for it themselves, at monthly costs that can reach several hundred euros.

Italy and Spain have taken broadly similar positions, with Italian classification leaving the drugs unreimbursed. France has been more willing, with favourable opinions from its health authority, but attached to tight eligibility rules.

The awkward result is that several European countries formally recognise obesity as a disease while declining to fund the medicines that treat it. Add the orforglipron licensing delay on top of that, and the gap between what a European patient could have and what they can actually get keeps widening.

What this means if you are in the UK

You now have two licensed oral options plus the injectables, which is more choice than patients in most of Europe have.

Practically, that means a conversation with a prescriber about which format suits your life and your tolerance rather than taking whatever happens to be available. If needles were the barrier, they no longer have to be. If a 30-minute wait before your morning coffee sounds unmanageable, orforglipron removes that constraint.

The realistic expectation on cost is that private prescribing arrives first. No UK price for orforglipron has been announced yet, and any figure circulating before pharmacies publish theirs is guesswork. Small-molecule tablets are cheaper to make at scale than peptide injections and need no cold chain, which points towards competitive pricing over time, but pointing towards something is not the same as arriving there.

One consistent warning applies to everyone. Every GLP-1 medicine in the UK is prescription-only, supplied through registered pharmacies. New approvals reliably attract counterfeit sellers, and the MHRA has been clear that buying from unregulated sources carries serious risk. It is also against the law to promote prescription-only weight management medicines to the public, so an advert pushing a named product at you is itself a warning sign.

What to watch over the next few months

Three dates and decisions will shape how this plays out.

NICE publishes on orforglipron on 18 November 2026, which determines whether NHS patients get access and on what terms. Expect any positive recommendation to come with prioritisation rules rather than open prescribing, following the pattern set by tirzepatide.

An EU decision on orforglipron will land at some point, and the length of that delay will tell you whether the Wegovy pill gap of five weeks was a one-off or the new normal.

And national reimbursement positions across Europe are under growing political pressure. Manufacturers have been lobbying hard, particularly in Germany. A shift there would matter more for European access than any regulator’s timeline.

Frequently asked questions

Is orforglipron available in the EU? 

Not yet. It holds a UK licence as of 10 August 2026 and a US licence from April 2026, but no European Commission marketing authorisation has been granted.

Why did the UK approve it before the EU? 

The MHRA can recognise assessments from other trusted regulators, including the FDA, which allows a shorter review when a medicine is already approved elsewhere. The EU centralised procedure runs its own full assessment.

Does UK approval mean the NHS will prescribe it? 

No. Funding is decided separately by NICE, with guidance due on 18 November 2026.

Can EU patients get it prescribed privately? 

No. A medicine without a marketing authorisation cannot legally be prescribed or dispensed in a member state, whether privately or otherwise.

Which pill produces more weight loss? 

Trial data favours oral semaglutide on average, but the two have never been compared head to head, and orforglipron has no food or water restrictions. The better option depends on the individual patient.

Bottom Line

Britain has built a regulatory route that gets medicines licensed early, and orforglipron is the clearest proof yet that it works. The EU is slower on licensing and, in several of its largest markets, considerably slower on paying.

Neither system is delivering treatment quickly to the people who need it most. The UK licences fast and funds slowly. The EU licences slowly and, in Germany, Italy and Spain, largely decline to fund at all. For patients on either side, the distance between an approval headline and a prescription they can afford remains the part that actually matters.

This article is for information only and is not medical advice. Speak to a GP, pharmacist or prescriber about whether any weight-management medicine is appropriate for you.

Sources

1. Medicines and healthcare products Regulatory Agency. The UK is the first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK, 10 August 2026. 
2. The Pharmacist. Eli Lilly’s new weight-loss pill is authorised by the MHRA. 10 August 2026. 
3. The Pharmaceutical Journal. MHRA approves orforglipron weight-loss pill. August 2026. 
4. The Pharmacist. Wegovy, the weight-loss pill, is the first to get approval in the UK. June 2026.
5. The Pharmacist. The Wegovy pill goes on sale in UK pharmacies. 6 July 2026. 
6. Novo Nordisk. Wegovy pill recommended by CHMP for approval in the EU. 22 May 2026.
7. Novo Nordisk. European Commission approval of Wegovy pill as the first oral GLP-1 for weight management in the EU. 15 July 2026. EMJ GOLD. Europe is set to get the first oral GLP-1 weight loss pill (OASIS 4 results). May 2026. 
8. EurekAlert. Post-hoc analysis of daily oral orforglipron in adults over 65, confirming the FDA approval date of 1 April 2026. May 2026. 
9. National Institute for Health and Care Excellence. Orforglipron for managing overweight and obesity, in development [GID-TA11650], publication due 18 November 2026.
10. Precision for Medicine. MHRA’s International Recognition Procedure: fast-track access to the UK market. December 2025. 
11. ProPharma Group. UK International Recognition Procedure: accelerating UK market access after FDA approval, including the joint MHRA and NICE pathway from 1 April 2026. June 2026. 
12. Value in Health. Worth their weight? An overview of the initial reimbursement decisions for GLP-1s in the EU5.
13. The Munich Eye: German court rules weight-loss injections classified as lifestyle medications. June 2026.
14. Petauri. The global obesity market access landscape: how evidence and policy are redefining reimbursement. February 2026.
15. Medicines and healthcare products Regulatory Agency. Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management. GOV.UK.